Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Clarity Pharmaceuticals a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Is pleased to announce it will be commencing a pivotal...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial...

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

BioCare, a leader in specialty pharmaceutical distribution, is excited to announce its new partnership with AeroSafe Global, a pioneer in reliable, sustainable cold chain solutions. This collaboration introduces an innovative, reusable...

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities...

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

The ISCT Institute of Training & Development, a division of the International Society for Cell and Gene Therapy (ISCT), has become the first cell and gene therapy (CGT) organization to receive globally recognized accreditation from the ANSI...

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Repare Therapeutics Inc. a leading clinical-stage precision oncology company, reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor, combined with palliative radiation for the...

FDA approves Bristol Myers Squibb's COBENFY™, a novel treatment for adult schizophrenia.

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. COBENFY represents the first new...

Galmed releases Phase 3 Aramchol results in Hepatology.

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients...

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis....

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

nuBioAge, a longevity science and wellness network based in West Palm Beach, has announced a partnership between their new comprehensive assessment and research center, nuHx, and Marius Pharmaceuticals, the company behind KYZATREX® (testosterone...

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime....

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness and MECOTEC are proud to announce an exciting new partnership that brings together two industry leaders in the field of cryotherapy and wellness services. As part of this collaboration, MECOTEC has acquired Restore's...

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

The capsules and tablets commonly used today consist of loose or lightly compressed particles of the drug and excipients. After ingestion, they disintegrate almost immediately in the stomach. The small drug particles then flow from the stomach and...

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

ChromaDex Corp. the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen®...